Alerta

BREATH TESTING DEVICES AND ANALYTICS

Resumen de: WO2025184435A1

The present invention provides an improved breath analyzer and breath test method to determine the presence of disease in humans, including but not limited to, H. pylori infection, Celiac Disease, Metabolic dysfunction-associated steatohepatitis (MAHD), Inflammatory Bowel Disease (JBD). 'm a subject's digestive tract. In certain embodiments, the present invention provides a universal breath testing platform and methods of testing for diseases of the gastrointestinal tract, the liver, the kidneys, and the lungs, along with testing for cancer, infections, and metabolic diseases.

DIAGNOSIS OF IMMUNE-MEDIATED INFLAMMATORY DISEASES USING MMP12 AS INDICATOR, AND MEDICINE FOR TREATING IMMUNE-MEDIATED INFLAMMATORY DISEASES VIA MMP12 INHIBITION

Resumen de: EP4610657A1

Provided are a method for detecting an immune-mediated inflammatory disease characterized by an increase in expression of MMP12, in a subject, a diagnostic drug containing a substance that specifically interacts with MMP12, and a therapeutic agent containing an MMP12 inhibitory substance.

Treatment target of inflammatory bowel disease and application thereof

Resumen de: CN120577530A

The invention discloses a therapeutic target for inflammatory bowel disease and application thereof. Research finds that NO can be combined with an enzyme active site of a CYP450 family member, so that the activity of the CYP450 family member is inhibited, finally generation of a pathogenic factor GM-CSF is inhibited, and enteritis is relieved. On the basis, an inflammatory bowel disease product, a kit and an analysis system are developed. According to the invention, a new strategy can be provided for preventing, detecting and treating intestinal inflammatory diseases, and the intestinal homeostasis imbalance can be effectively improved.

REGULATION OF GENES IN ULCERATIVE COLITIS AND THE USES THEREOF

Resumen de: MX2025009868A

The present disclosure generally relates to methods, and diagnostic applications, for the treatment of ulcerative colitis. More particularly the methods and diagnostic applications of the present invention relate to expression profiles of certain gene transcripts in ulcerative colitis patients and the usefulness of the expression profiles of these gene transcripts for the treatment, and/or diagnostic use in a subgroup of patients having ulcerative colitis.

TNFSF15 DCR3 VARIANTS OF TNFSF15 AND DCR3 ASSOCIATED WITH CROHN'S DISEASE

Resumen de: US2025243548A1

Described herein are methods and compositions related to the discovery of associations in TNFSF15 15 and DcR3 genetic loci across in Caucasian, Puerto Rican, and Korean Crohn's Disease, as demonstrated via trans-ethnic fine mapping. The present invention provides methods of quantifying risk and diagnosing susceptibility to Crohn's disease in a subject by determining the presence of one or more risk variants are at the TNFSF15 (or TL1A) and/or DcR3 genetic loci.

Compositions and methods for ibd patients using stool-derived eukaryotic nucleic acids

Nº publicación: IL322246A 01/09/2025

Solicitante:

GENEOSCOPY INC [US]
BARNELL ERICA [US]
BARNELL ANDREW [US]
WURTZLER ELIZABETH [US]
GHANNAM RYAN [US]
ROBERTS RICHARD [US]
GENEOSCOPY INC,
BARNELL Erica,
BARNELL Andrew,
WURTZLER Elizabeth,
GHANNAM Ryan,
ROBERTS Richard

Resumen de: AU2024213250A1

The present disclosure provides compositions and methods for using stool-derived, eukaryotic, nucleic acid biomarkers to diagnose disease, assess disease activity, monitor mucosal healing, and predict therapeutic response. The described biomarkers can be used by practitioners to better diagnose, manage, and treat inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD).